# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
EF Hutton analyst Tony Butler reiterates Apexigen (NASDAQ:APGN) with a Hold and maintains $0.64 price target.
Gainers Minerva Surgical, Inc. (NASDAQ: UTRS) shares jumped 209.1% to $0.5622 after the United States Patent and Trademark ...
Pyxis Oncology (NASDAQ:PYXS) has announced an acquisition of Apexigen (NASDAQ:APGN) that is expected to be completed in the sec...
EF Hutton analyst Tony Butler maintains Apexigen (NASDAQ:APGN) with a Buy and lowers the price target from $8 to $5.